有这六项创新 患者可能比医生更清楚如何使用抗生素

2015-06-19 佚名 奇点网

我们都知道,抗生素耐药性在不断提高。如果找不到解决这个问题的办法,结果会很糟糕:世界范围内可能会有数百万人死于本可以被轻松治好的疾病,很多常规手术的风险会变高,医疗成本也可能迅猛增长。如果不及时采取措施保证抗生素的效果,那么到了2050年,我们每年可能要承受大约100万亿美元的经济损失,以及1000万人因此死亡的悲惨局面。 解决这个问题的一个办法是:减少抗生素的不合理使用,也就是通过检测

我们都知道,抗生素耐药性在不断提高。如果找不到解决这个问题的办法,结果会很糟糕:世界范围内可能会有数百万人死于本可以被轻松治好的疾病,很多常规手术的风险会变高,医疗成本也可能迅猛增长。如果不及时采取措施保证抗生素的效果,那么到了2050年,我们每年可能要承受大约100万亿美元的经济损失,以及1000万人因此死亡的悲惨局面。
 
解决这个问题的一个办法是:减少抗生素的不合理使用,也就是通过检测来判别一种病症是否需要使用抗生素,以及应该使用哪种抗生素。奖金高达1500万美元的“经度大奖”(Longitude Prize)就旨在激励大学、公司和个人研发各类检测工具。
 
当然,以前我们也可以在实验室做这种检测,但问题是这个过程太复杂。正如评奖委员会成员罗杰·海菲尔德(Roger Highfield)所说:“通常而言医生要用棉签获取患者的组织,然后送去实验室进行培养分析。即便你嗓子疼得不行,我们的工具设备也无法立即就给出分析诊断结果。” 所以便捷、快速,智能是“经度大奖”对这类检测设备的要求。
 
“经度大奖”的名字来源于1714年英国政府发起的一个旨在解决“经度问题”的挑战赛。那时候航海家无法精确绘制经度,因此英国每年都会损失大批船舶。为了激励航海创新,英国政府举办了一个挑战赛。当然它对航海技术进步起到了一定作用,但效果并不是特别明显。
 
三百年后的今天,公共创新领域的竞赛又一次复兴,大量像X Prize这样的大奖赛应运而生。“经度大奖”由非营利性创新组织Nesta举办, 已经举办了五年多。每隔几个月,组委会就会颁发一次大奖。截至目前,全世界共有75个团队参加了比赛。下面是六个评奖委员会成员推荐的创意。
 
· 身体扫描仪
 

 
身体扫描仪的灵感来源于《星际迷航》里的三录仪。该设备可以使用红外线激光器来“分析血液化学成分”,从而揭示“特定细菌的免疫特点”。身体扫描仪仅需要触碰一下皮肤就能分析人体生命体征,然后可以将数据传输给另一台电脑。市面上已经有很多类似于三录仪这样的设备,还有很多同类设备正处于研发阶段。虽然图中的无创式血糖监测仪与检测抗药性无关,但它正是身体扫描仪家族的一员。
 
· 手机配件设备
 
 
同样,以手机配件形式出现的检测设备也令人期待。这类设备本身能耗很低,具备较小的处理能力。一般而言,人们都是利用手机完成必要的分析和数据存储。评奖委员会说:“移动设备日益普及可能对廉价新奇诊断设备领域出现重大突破具有潜在促进作用。”
 
· 棒棒糖式链球菌检测
 
 
这是一款棒棒糖形状的检测设备,能检测链球菌性喉炎。如果设备在病人体内发现了链球菌,自身就会改变颜色。这款设备的意义何在?全世界每年都会有上百万人因为嗓子疼而去看医生,其中一部分人是因为细菌感染,另一部分人则是因为其它原因。
 
· 测流检测
 
 
这款设备和验孕棒差不多,能检测尿液、 血液和唾液样本。它利用毛细管作用,一旦目标分子出现就会呈现出一道细线。这样一来,医生就能立即知道患者究竟感染了什么。海菲尔德说:“我们可以用它来寻找特定遗传标记,比如那些涉及抗生素耐药性的遗传标记。”
 
· 纳米机器人
 
 
纳米机器人作用很大。我们大胆推测这种机器人可以在人体内“漫步”,不断反馈体内各类细菌的情况。评奖委员会说:“纳米机器人既具备基本功能,又具备先机专业功能。它所携带的测量工具可以监控人体健康。比如它们可以评估炎症症状,而炎症一般意味着感染。”
 
· 迷你实验室
 
 
最终诊断设备可能以迷你实验室形式出现,具备同时分析检测多种样本的能力。这款设备具有检测十种不同类型感染的潜能,还可以检测人们对常规抗生素的耐药性。
 
当然,分析检测抗生素耐药性只是我们解决问题的一个途径而已。我们还可以通过减少药物使用(尤其是在农业领域减少药物使用)、寻找更好的办法跟踪药物使用情况以及为新药研发提供更大激励等方式应对抗生素耐药性提升。专家说,虽然大型制药公司过度使用抗生素给我们带来了担忧,但是目前他们几乎没有动力去研究分析抗生素问题。

原始出处:

6 Ideas For Fighting The Rise Of Antibiotic Resistance

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=29158, encodeId=4120291587d, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:47:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285212, encodeId=bc2e128521250, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jun 21 08:43:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28297, encodeId=38722829e0d, content=非常好的材料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28298, encodeId=d52c28298c5, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28299, encodeId=d8f7282990a, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28277, encodeId=d7fb282e72c, content=期待发展!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sat Jun 20 16:21:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28252, encodeId=ab2428252b8, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sat Jun 20 00:10:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-25 huaxipanxing

    看看

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=29158, encodeId=4120291587d, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:47:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285212, encodeId=bc2e128521250, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jun 21 08:43:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28297, encodeId=38722829e0d, content=非常好的材料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28298, encodeId=d52c28298c5, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28299, encodeId=d8f7282990a, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28277, encodeId=d7fb282e72c, content=期待发展!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sat Jun 20 16:21:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28252, encodeId=ab2428252b8, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sat Jun 20 00:10:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=29158, encodeId=4120291587d, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:47:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285212, encodeId=bc2e128521250, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jun 21 08:43:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28297, encodeId=38722829e0d, content=非常好的材料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28298, encodeId=d52c28298c5, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28299, encodeId=d8f7282990a, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28277, encodeId=d7fb282e72c, content=期待发展!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sat Jun 20 16:21:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28252, encodeId=ab2428252b8, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sat Jun 20 00:10:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-21 18619c0a62m

    非常好的材料

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=29158, encodeId=4120291587d, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:47:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285212, encodeId=bc2e128521250, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jun 21 08:43:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28297, encodeId=38722829e0d, content=非常好的材料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28298, encodeId=d52c28298c5, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28299, encodeId=d8f7282990a, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28277, encodeId=d7fb282e72c, content=期待发展!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sat Jun 20 16:21:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28252, encodeId=ab2428252b8, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sat Jun 20 00:10:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-21 18619c0a62m

    期待进一步研究

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=29158, encodeId=4120291587d, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:47:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285212, encodeId=bc2e128521250, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jun 21 08:43:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28297, encodeId=38722829e0d, content=非常好的材料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28298, encodeId=d52c28298c5, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28299, encodeId=d8f7282990a, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28277, encodeId=d7fb282e72c, content=期待发展!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sat Jun 20 16:21:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28252, encodeId=ab2428252b8, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sat Jun 20 00:10:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-21 18619c0a62m

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=29158, encodeId=4120291587d, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:47:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285212, encodeId=bc2e128521250, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jun 21 08:43:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28297, encodeId=38722829e0d, content=非常好的材料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28298, encodeId=d52c28298c5, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28299, encodeId=d8f7282990a, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28277, encodeId=d7fb282e72c, content=期待发展!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sat Jun 20 16:21:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28252, encodeId=ab2428252b8, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sat Jun 20 00:10:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-20 yydlt

    期待发展!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=29158, encodeId=4120291587d, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:47:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285212, encodeId=bc2e128521250, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Jun 21 08:43:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28297, encodeId=38722829e0d, content=非常好的材料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28298, encodeId=d52c28298c5, content=期待进一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28299, encodeId=d8f7282990a, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Sun Jun 21 00:14:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28277, encodeId=d7fb282e72c, content=期待发展!, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sat Jun 20 16:21:00 CST 2015, time=2015-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28252, encodeId=ab2428252b8, content=?, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Sat Jun 20 00:10:00 CST 2015, time=2015-06-20, status=1, ipAttribution=)]
    2015-06-20 summer474cn

    0

相关资讯

Sci trans med:新一代抗生素成功抵抗耐药菌

基于结构对早期使用的抗生素奇霉素进行化学修饰,科学家们研发出了新一代奇霉素抗生素。第二代奇霉素能抑制对各种抗生素耐受的肺炎链球菌的生长,并对导致呼吸道疾病的嗜血杆菌和卡塔莫拉菌的抗菌能力增强,对军团杆菌和性传播的淋球菌和衣原体的抗菌能力也有所增强。 细菌的耐药性问题越来越严重,正常剂量的药物无法发挥应有的杀菌效果,给疾病的治疗造成困难。目前认为抗药性的产生是微生物基因突变造成的。为防止和减少抗药

中国一年用掉十几万吨抗生素 占全球一半用量

据中国之声报道,本月11号,中国科学院广州地球化学研究所一项研究结果显示,2013年中国抗生素总使用量约为16.2万吨,其中48%为人用抗生素,我国滥用抗生素的情况相当严重。实际情况究竟怎样?滥用抗生素对人体有哪些危害?  世界卫生组织曾多次表示,如果抗生素的滥用造成细菌的耐药性,细菌是不分国界的,当人类面临传染病的时候,可能出现无药可用的危险状况。  今年5月,世界卫生组织发布名为《抗菌素耐药:

Nat Chem Biol:新型抗菌化合物可有效抵御耐药病原体且毒性较低

靶向攻击真菌感染而不损伤人类细胞的新型化合物或许可以有效避免抗生素耐药性的产生;近日,刊登在国际杂志Nature Chemical Biology上的一篇研究论文中,来自伊利诺伊大学的研究人员通过研究开发并且检测了抗真菌药物两性霉素B的多种衍生物。两性霉素B医生们推出的最后一道抵御真菌感染的防御性药物,该药已经使用了近半个世纪,其被认为可以有效克服新生的耐药性病原体的感染。 研究者Burke表

世卫组织通过抗微生物药物耐药性决议

第68届世界卫生大会25日通过应对抗微生物药物耐药性决议,敦促世界卫生组织各成员重视抗微生物药物面临的耐药性问题并采取行动。    世卫组织称,出现在全世界各地的抗微生物药物耐药性(包括抗生素耐药性)是最为紧迫的抗药趋势,它削弱了治疗传染性疾病的能力和其他许多卫生与医药方面的进展。    这项名为“抗微生物药物耐药性全球行动计划”的决议设

中国河流抗生素地图发布 阿莫西林浓度**

  中国抗生素污染总体情况到底如何?终于有了研究成果。近日,中国科学院广州地球化学研究所应光国课题组获取首份中国抗生素使用量和排放量清单,预测得出全国5 8个流域的“抗生素环境浓度地图”。这一报告于6月初发表在国际学术期刊《环境科学与技术》。   近年多地河流水体被检出抗生素,已经引起人们的广泛关注。去年12月,央视曝光全国主要河流部分点位都检出抗生素,甚至南京居民家中自来水也有检出。其

The Lancet:婴儿严重细菌感染:简化用药方案vs普鲁卡因青霉素联合庆大霉素

2015年5月,发表于《Lancet》的一篇文章比较了资源贫乏地区具有严重感染临床指征且不能转诊的婴儿使用简化抗生素方案与为期7天的注射用普鲁卡因青霉素联合庆大霉素的疗效。结果显示,3种简化方案与注射用普鲁卡因+庆大霉素治疗7天的方案一样有效。背景:WHO建议0~59天的可能具有严重细菌感染临床指征的小婴儿进行基于医院的治疗,但是较差资源地区的多数家庭不能接受转诊。因此,我们旨在评估,对于不能转诊